Pharmacology News and Research

Latest Pharmacology News and Research

Evotec revenues for first-half of 2010 increase 33% to € 25.0 m

Evotec AG today reported financial results and corporate updates for the first half of 2010.

12 Aug 2010

Ohio State University procures IonFlux 16 high throughput automated patch clamp instrument

Fluxion Biosciences, Inc. announced today that the Ohio State University Department of Pharmacology has purchased the IonFlux 16, the first high throughput automated patch clamp instrument of its kind geared towards the academic researcher. The IonFlux instrument will enable large scale pharmacology experiments on this group's nAChR targets, which previously were not feasible using a manual patch clamp rig.

From Fluxion Biosciences 11 Aug 2010

Silence Therapeutics receives patent for RNA silencing method

Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.

11 Aug 2010

AssureRx Health achieves CAP accreditation for laboratory pharmacogenetic testing services

AssureRx Health, Inc. today announced that it has received accreditation from the College of American Pathologists for the delivery of high-quality, reliable laboratory pharmacogenetic testing services that meet or exceed regulatory laboratory standards and ensure commitment to patient care.

11 Aug 2010

PAREXEL International fourth-quarter consolidated service revenue increases 19.4% to $295.3 million

PAREXEL International Corporation today reported financial results for the fourth quarter and fiscal year ended June 30, 2010.

From Parexel 10 Aug 2010

Scientific paper explains impact of visual cycle modulation in neurovascular retinopathy

Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that a scientific paper co-authored by Ryo Kubota, M.D., Ph.D., chairman, president and chief executive officer of Acucela, has been published in Experimental Eye Research. The paper, "Visual Cycle Modulation in Neurovascular Retinopathy" was also co-authored by scientists from Children's Hospital and Harvard Medical School in Boston and demonstrates for the first time the impact of treatment with a visual cycle modulator (VCM) on retinopathy in an immature eye.

10 Aug 2010

Loyola University forms new institute for molecular level disease research

Loyola University Chicago Stritch School of Medicine has formed a new research institute dedicated to understanding the molecular causes of cancer, autoimmune disorders, cardiovascular disease and several other illnesses.

10 Aug 2010

Scientist to research on molecular machinery of breast cancer

Someone in the world is diagnosed with breast cancer every 23 seconds. It is the leading cause of cancer death worldwide among women and approximately 456,000 die from the disease each year. At The University of Texas Health Science Center at Houston (UTHealth), a scientist is taking aim at the molecular machinery behind this disease.

10 Aug 2010

EpiCept second-quarter net loss decreases to $4.9 million

EpiCept Corporation today announced operating and financial results for the three and six months ended June 30, 2010, and provided an update with respect to the Company's key business initiatives.

7 Aug 2010

Ardea Biosciences second-quarter total revenues decline to $3.5 million

Ardea Biosciences, Inc., a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, reported recent accomplishments and financial results for the second quarter and six months ended June 30, 2010.

7 Aug 2010

Drugs that reduce activity of ABDH6 enzyme can prevent brain damage: Study

A newly discovered molecular mechanism helps control the amount and effectiveness of a substance that mimics an active ingredient in marijuana, but that is produced by the body's own nerve cells.

7 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

New MIC platform measures cell-signaling pathways in brain tumor samples at single-cell level

New technologies for the diagnosis of cancer are rapidly changing the clinical practice of oncology. As scientists learn more about the molecular basis of cancer, the development of new tools capable of multiple, inexpensive biomarker measurements on small samples of clinical tissue will become essential to the success of genetically informed and personalized cancer therapies.

4 Aug 2010

Master model to track mercury movement from original emission source to humans

University of Louisville Public Health doctoral student Caroline Chan is working to create scientific tools to help environmental policy decision makers evaluate and modify mercury emission regulations.

3 Aug 2010

Axiogenesis signs non-exclusive license agreement with iPS Academia

Axiogenesis AG and iPS Academia Japan Inc. (Kyoto, Japan) announced that they have executed a non-exclusive agreement with iPS Academia (Kyoto, Japan) through which Axiogenesis obtains worldwide access to the extensive portfolio of induced pluripotent stem cell technology for iPSC-derived cardiomyocytes and other cell types, pioneered by Professor Shinya Yamanaka, Center for iPS Cell Research and Application at the University of Kyoto, Japan.

3 Aug 2010

Menstrual cycle affects body's response to tracheal intubation: Research

In women undergoing surgery, the heart rate and blood pressure response to ventilation tube placement varies at different times of the menstrual cycle, according to a study in the August issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

3 Aug 2010

Etoricoxib better than opioid drug tramadol for postoperative pain: Study

For patients with moderate pain after foot surgery, the cyclo-oxygenase 2 (COX-2) inhibitor drug etoricoxib provides better pain relief with fewer side effects than the opioid drug tramadol, concludes a study in the August issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

3 Aug 2010

BioMarin provides update on PEG-PAL Phase 2 clinical study for phenylketonuria

BioMarin Pharmaceutical Inc. announced today an update in the Phase 2 clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of phenylketonuria (PKU). Data reported in this announcement reflect preliminary results as of July 23, 2010. Complete top-line results are expected in the fourth quarter of 2010.

3 Aug 2010

Intra-Cellular Therapies ITI-007 Phase Ib/II clinical trial for schizophrenia meets primary endpoint

Intra-Cellular Therapies, Inc. today announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company's unique, investigational new drug for the treatment of schizophrenia. The trial met its primary endpoint demonstrating that ITI-007 was safe and well-tolerated in patients with stabilized schizophrenia.

30 Jul 2010

Clinical Pharmacokinetics Research Laboratory deploys AB SCIEX mass spectrometry technology

AB SCIEX, a global leader in life science analytical technologies, today announced that the Clinical Pharmacokinetics Research Laboratory at the University of Rhode Island's College of Pharmacy is using AB SCIEX mass spectrometry technology to develop a novel test that would enable clinical researchers to use saliva to monitor immunosuppressant drugs commonly administered to make organ transplants successful.

28 Jul 2010